Company: BSX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0000885725-25-000026
Chunk: 61

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 61
---
 certain litigation-related net charges (credits) and EU MDR implementation costs(124)Amortization expense(214)Operating income (loss) 675 Other income (expense), net(67)Income (loss) before income taxes$608 (1) Includes royalty expense.(2) Calculated as Net sales of reportable segments less Segment expenses. Three Months Ended March 31,Depreciation expense (in millions)20252024MedSurg$27 $24 Cardiovascular78 66 Consolidated depreciation expense$106 $90 As ofTotal assets (in millions)March 31, 2025December 31, 2024MedSurg$3,127 $3,093 Cardiovascular7,413 7,084 Total assets of reportable segments10,540 10,177 Goodwill17,340 17,089 Other intangible assets, net6,566 6,684 All other corporate assets5,695 5,446  $40,140 $39,395 

29

As ofLong-lived assets (in millions)March 31, 2025December 31, 2024U.S.$1,522 $1,461 Ireland655 631 Costa Rica557 530 Other countries654 672 Property, plant and equipment, net3,389 3,294 Goodwill17,340 17,089 Other intangible assets, net6,566 6,684 Operating lease right-of-use assets in Other long-term assets448 449  $27,743 $27,516 

NOTE K – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.Three Months Ended March 31,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$420 $253 $673 $395 $247 $642 Urology469 165 633 356 157 513 Neuromodulation204 67 271 190 66 256 Med